GSA Capital Partners’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16K | Sell |
10,963
-32,978
| -75% | -$48.1K | ﹤0.01% | 1692 |
|
|
2025
Q1 | $70K | Buy |
+43,941
| New | +$70K | 0.01% | 1532 |
|
|
2024
Q4 | – | Sell |
-15,446
| Closed | -$88K | – | 1641 |
|
|
2024
Q3 | $88K | Sell |
15,446
-7,822
| -34% | -$44.6K | 0.01% | 1502 |
|
|
2024
Q2 | $107K | Sell |
23,268
-25,495
| -52% | -$117K | 0.01% | 1525 |
|
|
2024
Q1 | $398K | Buy |
+48,763
| New | +$398K | 0.03% | 1042 |
|
|
2023
Q3 | – | Sell |
-312,135
| Closed | -$858K | – | 1526 |
|
|
2023
Q2 | $858K | Buy |
312,135
+135,084
| +76% | +$371K | 0.09% | 401 |
|
|
2023
Q1 | $556K | Buy |
177,051
+162,419
| +1,110% | +$510K | 0.06% | 643 |
|
|
2022
Q4 | $86K | Sell |
14,632
-5,273
| -26% | -$31K | 0.01% | 1320 |
|
|
2022
Q3 | $175K | Sell |
19,905
-2,439
| -11% | -$21.4K | 0.02% | 1265 |
|
|
2022
Q2 | $168K | Buy |
+22,344
| New | +$168K | 0.03% | 1112 |
|